Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mikiya Ishihara
Observed names:
Ishihara, Mikiya,
M Ishihara,
M. Ishihara,
MIKIYA ISHIHARA
Institution:
Osaka International Cancer Institute
Observed institutions:
Mie University,
Mie University Hospital,
National Cancer Center Hospital East,
Osaka International Cancer Institute,
Japanese Breast Cancer Society
ORCID:
0000-0002-7581-2615
Observed ORCID:
0000-0002-7581-2615
OpenAlex ID:
A5009512419
Works
93
Awards
2
Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
2015
·
Shinichi Kageyama
, Hiroaki Ikeda
, et al.
·
Clinical Cancer Research
·
205
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
2022
·
Mikiya Ishihara
, Shigehisa Kitano
, et al.
·
Journal for ImmunoTherapy of Cancer
·
75
PDF
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
2020
·
Tatsunori Shimoi
, Shigenori E. Nagai
, et al.
·
Breast Cancer
·
73
PDF
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
2023
·
Mitsuo Terada
, Aki Ito
, et al.
·
Breast Cancer
·
71
PDF
A phase 1 trial of NY‐ESO ‐1‐specific TCR ‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma
2023
·
Mikiya Ishihara
, Yoshihiro Nishida
, et al.
·
International Journal of Cancer
·
65
PDF
MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
2020
·
Mikiya Ishihara
, Shinichi Kageyama
, et al.
·
BMC Cancer
·
58
PDF
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
2020
·
Mikiya Ishihara
, Yasutaka Tono
, et al.
·
Cancer Immunology Immunotherapy
·
51
PDF
Retrospective Analysis of Risk Factors for Central Nervous System Metastases in Operable Breast Cancer: Effects of Biologic Subtype and Ki67 Overexpression on Survival
2012
·
Mikiya Ishihara
, Hirofumi Mukai
, et al.
·
Oncology
·
51
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023
·
Akira Kawai
, Mikiya Ishihara
, et al.
·
Clinical Cancer Research
·
37
PDF
First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer
2019
·
Hiroyasu Oda
, Mikiya Ishihara
, et al.
·
Case Reports in Oncology
·
32
HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinations
2002
·
K Mukai
, Y Yasutomi
, et al.
·
Gene Therapy
·
24
CD204‑positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand‑1 expression
2020
·
Mayuko Nagano
, Kanako Saito
, et al.
·
Oncology Letters
·
13
PDF
Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor
2014
·
Mikiya Ishihara
, Naohiro Seo
, et al.
·
PLoS ONE
·
13
PDF
Risk factors for cisplatin‑induced acute kidney injury: A pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice
2020
·
Hiroyasu Oda
, Toshiro Mizuno
, et al.
·
Molecular and Clinical Oncology
·
12
PDF
Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer
2023
·
CHIHIRO HIGASHI
, KANAKO SAITO
, et al.
·
Anticancer Research
·
11
PDF
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial
2022
·
Satoshi Okumura
, Mikiya Ishihara
, et al.
·
BMJ Open
·
9
PDF
Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer.
2019
·
Mikiya Ishihara
, Shigehisa Kitano
, et al.
·
Journal of Clinical Oncology
·
7
[A Case of Poorly Differentiated Carcinoma of Unknown Primary Site with Risk of Choriocarcinoma Syndrome Effectively Treated with Reduced Bleomycin,Cisplatin ,Etoposide Combination Regimen(BEP Regimen)].
2018
·
Motohiko Okano
, Hiroyasu Oda
, et al.
·
PubMed
·
7
Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers
2018
·
Yasutaka Tono
, Mikiya Ishihara
, et al.
·
Oncotarget
·
7
PDF
αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence
2023
·
Mikiya Ishihara
, Hiroshi Miwa
, et al.
·
iScience
·
6
Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma.
2023
·
Akira Kawai
, Mikiya Ishihara
, et al.
·
Journal of Clinical Oncology
·
6
Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer
2022
·
Akira Tsunoda
, Toshiro Mizuno
, et al.
·
Case Reports in Oncological Medicine
·
6
PDF
Evaluation of MAGE ‐ A4 expression in breast cancer and its impact on prognosis
2024
·
Kaho Nakamura
, Kanako Saito
, et al.
·
Cancer Science
·
5
PDF
Long-Term Survival Outcomes and Risk Factors for Axillary and Locoregional Recurrence in Japanese Patients with Sentinel Node-Positive Breast Cancer Treated in Accordance with the ACOSOG Z0011 Strategy
2024
·
Yuri Oyama
, Nobuyoshi Kittaka
, et al.
·
Oncology
·
4
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
2023
·
Manabu Futamura
, Takahiro Nakayama
, et al.
·
Breast Cancer
·
4
PDF
Show more works
View as search
Works count:
93
Citation count:
887
H-index:
13
I10-index:
15
Year
Topic
Type